Altimmune to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will announce its second quarter 2022 financial results on August 11, 2022, followed by a conference call at 8:30 am E.T. to discuss these results and provide a business update. The call will be accessible via webcast on Altimmune's Investor Relations website. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide, targeting obesity and NASH. Altimmune is also advancing its HepTcell™ immunotherapeutic for chronic hepatitis B.

GAITHERSBURG, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2022 financial results on Thursday, August 11, 2022 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on August 11 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to twelve months.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:

Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
reisenstadt@altimmune.com

FAQ

When will Altimmune report its second quarter 2022 financial results?

Altimmune will report its second quarter 2022 financial results on August 11, 2022.

What time is Altimmune's conference call for financial results?

The conference call will take place at 8:30 am E.T. on August 11, 2022.

Where can I access Altimmune's conference call?

The conference call can be accessed via webcast on Altimmune's Investor Relations website.

What is Altimmune's lead product candidate?

Altimmune's lead product candidate is pemvidutide, which is developed for the treatment of obesity and NASH.

What other therapeutics is Altimmune developing?

Altimmune is also developing HepTcell™, an immunotherapeutic aimed at a functional cure for chronic hepatitis B.